Viz.ai’s Viz Recruit Platform Will Be Used to Expedite Patient Enrollment in PE-TRACT Trial

March 4, 2023—Viz.ai, a developer of artificial intelligence (AI)–powered disease detection and care coordination technology, announced that the company’s Viz Recruit platform will be used to optimize patient enrollment for the Pulmonary Embolism–Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial.

PE-TRACT, which is funded by the National Institutes of Health, is a randomized controlled clinical trial that is planned to enroll 500 patients at 30 to 50 sites.

According to Viz.ai, the PE-TRACT trial is designed to address whether catheter therapy should be routinely used to treat intermediate-risk pulmonary embolism versus anticoagulants alone. The investigating institutions in the PE-TRACT trial will use Viz Recruit to find, screen, and enroll clinical trial candidates.

Viz Recruit is an AI-powered clinical trial enrollment platform that automates the identification and triage of eligible candidates for pretrial review, while reducing the burden on the research team. Using Viz Recruit, sites will be able to automatically screen patients based on pulmonary embolism and high right ventricular to left ventricular diameter ratio.

The cloud-based technology helps to broaden the recruitment funnel in both size and diversity and streamlines the trial enrollment workflow. The Viz Recruit has been used to screen approximately 300,000 patients and identify more than 14,000 clinical trial candidates across 100 health care facilities, stated the company.

The principal investigator of the PE-TRACT trial is Akhilesh Sista, MD, an interventional radiologist on the faculty at Weill Cornell Medical College in New York, New York.

“The PE-TRACT trial will offer a deeper knowledge of pulmonary embolism by providing a comprehensive comparison of catheter-directed therapy plus anticoagulation to anticoagulation alone,” commented Dr. Sista in the company’s press release. “PE-TRACT will provide valuable insights to patients and providers regarding which approach best maintains cardiopulmonary health in the year following PE. Viz.ai’s Recruit tool has the potential to efficiently identify potential participants and help this important trial complete enrollment on time.”